NurExone Biologic Receives FDA Orphan-Drug Designation, Accelerating Development of ExoPTEN therapy for Acute Spinal Cord Injury Treatment

The orphan drug designation provides significant benefits to pharmaceutical companies developing drugs for rare diseases, i.e. those impacting fewer than 200,000 people in the United Statesii. These benefits include market exclusivity, financial incentives, regulatory assistance, and support with drug development. Overall, the designation incentivizes and supports the development of certain

Read More »

Appointment of Professor Teo Forcht Dagi to Scientific Advisory Board and Advisory Committee

TORONTO and HAIFA, Israel, Oct. 19, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company” or “NurExone”), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, is honored to welcome Professor Teodoro Forcht Dagi, a renowned neurosurgeon, life science

Read More »

NurExone Secures Eureka Grant for Collaborative Partnership to Expand to Chronic Spinal Cord Injury Therapy

The grant is for a collaboration with Canada-based Inteligex Inc. (“Inteligex”) to develop an innovative hybrid therapy tailored for the complex chronic spinal cord injury market. This endeavor combines Inteligex’s established expertise in stem cell treatments with NurExone’s ExoTherapy drug delivery platform. Currently, NurExone is in the process of developing

Read More »

NurExone and Particle Metrix Announce Collaboration in Extracellular Vesicles Analysis Using State-of-the-art Analytic Device

MUNICH, Germany and TEL AVIV, Israel, June 01, 2023 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (the “Company” or “NurExone”) (TSXV: NRX) (FSE: J90), a biopharmaceutical company developing biologically-guided exosome therapy (“ExoTherapy”) for patients with traumatic spinal cord injuries, is pleased to announce a pioneering collaboration with the German company, Particle

Read More »

Set layout popup